Sliding sugars offer simpler, smarter route to precision liver

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-08-31T23:36:18.380Z • Permanent link

Researchers at Kumamoto University have made a groundbreaking discovery in the field of targeted drug delivery, unlocking a simpler and smarter route to precision liver treatment. Led by Dr. Takashi Kishimoto, a renowned expert in drug delivery systems, the team has been working tirelessly to overcome the complex challenges of constructing the chemical key to enter liver cells. Their efforts have paid off, with the development of a novel sugar-based delivery system that has shown promising results in preclinical trials. The breakthrough has significant implications for the pharmaceutical industry, with major companies such as Pfizer and Merck already investing heavily in similar research initiatives.

Kumamoto University's collaboration with the National Institute of Advanced Industrial Science and Technology (AIST) has enabled the team to leverage cutting-edge technology and expertise in materials science and nanotechnology. The partnership has also provided access to significant funding and resources, allowing the researchers to accelerate their work and bring the project to fruition. With the support of these institutions, the team has been able to overcome some of the major hurdles associated with targeted drug delivery, including the need for highly specific and stable delivery systems.

The development of the sugar-based delivery system is a significant achievement, particularly given the complexity and cost of constructing traditional delivery systems. According to Dr. Kishimoto, "Our approach has the potential to revolutionize the field of targeted drug delivery, enabling the creation of highly specific and effective treatments for a range of diseases, including liver cancer and other liver disorders." The technology has already been patented, and the team is now working to scale up production and prepare for clinical trials.

The breakthrough in sugar-based delivery systems has significant implications for the pharmaceutical industry, particularly in the context of targeted drug delivery. Companies such as Pfizer and Merck are already investing heavily in similar research initiatives, and the development of more effective and targeted delivery systems is likely to be a major driver of innovation in the sector. According to a recent report by Grand View Research, the global targeted drug delivery market is expected to reach $24.8 billion by 2025, driven by increasing demand for more effective treatments for a range of diseases.

The development of sugar-based delivery systems also has significant implications for research communities and academic institutions. The technology has the potential to accelerate the discovery and development of new treatments for a range of diseases, enabling researchers to focus on more complex and challenging targets. According to Dr. Kishimoto, "Our approach has the potential to enable researchers to target specific cells and tissues, rather than simply delivering drugs to the entire body. This has the potential to revolutionize the field of targeted drug delivery and enable the creation of highly effective treatments for a range of diseases.

The development of sugar-based delivery systems is part of a larger trend in the field of targeted drug delivery, with multiple approaches and technologies being explored. Traditional approaches to targeted drug delivery have been limited by the need for highly specific and stable delivery systems, which have proven difficult to construct and deliver. In recent years, however, there has been a growing interest in alternative approaches, including the use of nanoparticles and other delivery systems. According to a recent report by MarketsandMarkets, the global nanoparticles market is expected to reach $43.8 billion by 2025, driven by increasing demand for more effective treatments for a range of diseases.